Loading
A phase 3 trial of Plerixafor and Filgrastim in Multiple myeloma, run by Case Comprehensive Cancer Center, recorded as terminated on the registry.
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide is a phase 3 interventional study registered as NCT01301963 by Case Comprehensive Cancer Center, with 9 participants recorded, started 2011-07 and due to reach its primary completion in 2013-06. Interventions recorded: plerixafor, filgrastim. Conditions recorded: Refractory Multiple Myeloma.
Linked to the drug Plerixafor because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Plerixafor, Filgrastim (G-CSF) and the tag pipeline.
Shares Plerixafor, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/